COVID-19: benefits and risks of passive immunotherapeutics

Figures & data

Figure 1. Schematic representation of convalescent plasma therapy

Figure 2. Schematic representation of neutralizing antibodies (nAbs) inhibiting viral membrane fusion and preventing replication

Table 1. Human nAbs against SARS-CoV-2, SARS-CoV, and MERS-CoV

Human nAb	Neutralizing pathogen	Mechanism
Recombinant Human 47D11 mAb	SARS-CoV-2 and SARS-CoV	Recognizes conserved epitope on spike RBD independent of receptor binding inhibition.
S109.8; S227.14 S230.15; mAbs	Human SARS-CoV with S mutants	Inhibits the binding of SARS-CoV RBD to ACE2 receptor
CR3022; CR3014 scFv; mAb	Live SARS-CoV, HKU-39849 and CR3014.	Recognizes epitopes on SARS-CoV RBD residues 318–510 with high affinity.
80 R; scFv; mAb	Live SARS-CoV infection	Recognizes epitopes on SARS-CoV S1 and blocks RBD-ACE2 binding.
S230.15; m396; mAbs	SARS-CoV strains	Recognizes epitopes on SARS-CoV S1 protein and interferes with RBD–ACE2 receptor interaction.
MERS-27; m336 Fab; MCA1; mAbs;	Strains of pseudo type MERS-CoV.	Recognizes epitopes on MERS-CoV RBD and blocks RBD-DPP4 receptor binding

Figure 3. Schematic representation of pathogen inactivation technologies